Al Nahdi Medical Company SJSC 4164.SR · SAR

Consumer Staples · Tadawul · 🇸🇦 Saudi Arabia

Compare

92.05

+1.15%

Close of 9 Nov 2026, in SAR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SAR, from our data supplier.

FY2025

Revenue

SAR 10.21bn

FY2017FY2025

Net income

SAR 830.7m

FY2017FY2025

Free cash flow

SAR 806.8m

FY2017FY2025

Shareholders' equity

SAR 2.74bn

FY2017FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	SAR 10.21bn	SAR 9.45bn	SAR 8.71bn	SAR 8.62bn	SAR 8.07bn	SAR 8.64bn	SAR 7.82bn	SAR 7.35bn	SAR 7.06bn
Gross profit	SAR 3.81bn	SAR 3.53bn	SAR 3.44bn	SAR 3.52bn	SAR 3.30bn	SAR 2.88bn	SAR 1.97bn	SAR 1.93bn	SAR 2.01bn
Operating income	SAR 907.6m	SAR 873.2m	SAR 961.0m	SAR 1.07bn	SAR 919.6m	SAR 959.3m	SAR 812.8m	SAR 667.5m	SAR 758.6m
Net income	SAR 830.7m	SAR 820.7m	SAR 892.6m	SAR 887.8m	SAR 812.5m	SAR 849.1m	SAR 692.0m	SAR 610.7m	SAR 721.2m
Diluted earnings per share	6.39	6.31	6.87	6.83	6.25	6.53	5.32	4.70	5.55

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Total assets	SAR 6.69bn	SAR 6.17bn	SAR 5.37bn	SAR 4.94bn	SAR 4.29bn	SAR 4.67bn	SAR 4.19bn	SAR 2.69bn	SAR 2.57bn
Cash and short-term investments	SAR 555.9m	SAR 956.8m	SAR 909.7m	SAR 1.08bn	SAR 401.0m	SAR 1.01bn	SAR 575.2m	SAR 370.4m	SAR 121.2m
Total liabilities	SAR 3.95bn	SAR 3.59bn	SAR 2.91bn	SAR 2.70bn	SAR 2.68bn	SAR 2.59bn	SAR 2.40bn	SAR 1.01bn	SAR 944.0m
Debt	SAR 1.78bn	SAR 1.53bn	SAR 1.17bn	SAR 1.17bn	SAR 1.36bn	SAR 1.24bn	SAR 1.22bn	SAR 1.5m	SAR 1.5m
Shareholders' equity	SAR 2.74bn	SAR 2.59bn	SAR 2.46bn	SAR 2.24bn	SAR 1.60bn	SAR 2.08bn	SAR 1.78bn	SAR 1.68bn	SAR 1.63bn
Shares outstanding	130m	130m	130m	130m	130m	130m	130m	130m	130m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Cash from operations	SAR 1.19bn	SAR 1.49bn	SAR 1.37bn	SAR 1.67bn	SAR 1.33bn	SAR 1.59bn	SAR 1.35bn	SAR 980.0m	SAR 910.7m
Capital spending	−SAR 387.1m	−SAR 384.5m	−SAR 384.5m	−SAR 275.2m	−SAR 306.5m	−SAR 319.8m	−SAR 234.4m	−SAR 183.0m	−SAR 178.0m
Free cash flow	SAR 806.8m	SAR 1.11bn	SAR 984.2m	SAR 1.39bn	SAR 1.03bn	SAR 1.27bn	SAR 1.11bn	SAR 797.0m	SAR 732.7m
Dividends paid	−SAR 728.0m	−SAR 715.0m	−SAR 715.0m	−SAR 300.3m	−SAR 1.26bn	−SAR 535.0m	−SAR 500.0m	−SAR 550.0m	−SAR 602.6m

Latest quarters

By quarter end

	Jun 2026	Mar 2026	Dec 2025	Sept 2025	Jun 2025	Mar 2025	Dec 2024	Sept 2024
Revenue	SAR 2.67bn	SAR 2.79bn	SAR 2.59bn	SAR 2.46bn	SAR 2.53bn	SAR 2.63bn	SAR 2.36bn	SAR 2.35bn
Gross profit	SAR 1.01bn	SAR 987.7m	SAR 1.08bn	SAR 812.0m	SAR 966.0m	SAR 950.9m	SAR 882.4m	SAR 851.0m
Operating income	SAR 245.9m	SAR 259.7m	SAR 211.2m	SAR 184.0m	SAR 260.6m	SAR 270.0m	SAR 192.3m	SAR 175.8m
Net income	SAR 215.2m	SAR 235.7m	SAR 175.9m	SAR 161.2m	SAR 238.4m	SAR 255.2m	SAR 157.8m	SAR 182.2m
Diluted earnings per share	1.66	1.81	1.35	1.24	1.83	1.96	1.21	1.40
Cash from operations	SAR 50.0m	SAR 857.0m	SAR 138.0m	SAR 526.0m	−SAR 124.0m	SAR 631.0m	SAR 362.0m	SAR 559.0m
Capital spending	−SAR 79.0m	−SAR 83.0m	−SAR 91.0m	−SAR 118.0m	−SAR 89.0m	−SAR 103.0m	−SAR 116.0m	−SAR 66.0m
Free cash flow	−SAR 29.0m	SAR 774.0m	SAR 47.0m	SAR 408.0m	−SAR 213.0m	SAR 528.0m	SAR 246.0m	SAR 493.0m
Total assets	SAR 6.81bn	SAR 7.41bn	SAR 6.69bn	SAR 6.76bn	SAR 6.38bn	SAR 6.53bn	SAR 6.17bn	SAR 5.91bn
Cash and short-term investments	—	—	SAR 555.9m	SAR 638.2m	SAR 691.9m	SAR 987.8m	SAR 956.8m	SAR 747.6m
Debt	—	—	SAR 420.2m	SAR 423.6m	SAR 754.1m	SAR 389.4m	SAR 383.5m	SAR 387.9m
Shareholders' equity	SAR 2.51bn	SAR 2.62bn	SAR 2.74bn	SAR 2.52bn	SAR 2.69bn	SAR 2.45bn	SAR 2.59bn	SAR 2.41bn

Financial ratios

Data as of 3 Oct 2026

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	37.3%	37.4%	39.4%	40.9%	41.0%	33.3%
Operating margin	8.9%	9.2%	11.0%	12.4%	11.4%	11.0%
Net margin	8.1%	8.7%	10.2%	10.3%	10.1%	9.8%
Return on equity	30.3%	31.7%	36.2%	39.6%	50.7%	40.8%
Return on assets	12.4%	13.3%	16.6%	18.0%	19.0%	18.2%
Free cash flow yield	13.3%	15.8%	14.8%	16.4%	13.9%	16.1%
Revenue growth	8.1%	8.4%	1.1%	6.8%	-6.7%	10.4%
Earnings growth	1.2%	-8.1%	0.5%	9.3%	-4.3%	22.7%
Current ratio	1.54x	1.55x	1.69x	1.70x	1.40x	1.72x
Debt to equity	0.15x	0.15x	0.12x	0.18x	0.23x	0.20x
Equity ratio	41.0%	41.9%	45.9%	45.4%	37.4%	44.6%
Interest coverage	6.40x	7.54x	11.57x	13.50x	11.66x	16.56x
Buybacks as a share of market value	0.0%	0.0%	0.0%	0.0%	0.0%	—

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	5.8%	3.4%	—
Operating income	-5.4%	-1.1%	—
Net income	-2.2%	-0.4%	—

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	37.3%	38.6%	38.1%	—

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022
Price to earnings	14.9	18.6	19.9	24.5
Price to sales	1.2	1.6	2.0	2.5

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 30 Mar 2026.

	FY2026	FY2025	FY2024	FY2023	FY2022
Paid in the year	3.00	5.60	5.50	5.50	2.31

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Al Nahdi Medical Company SJSC 4164.SR · SAR

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology